Search results: Sage Journals

Open accessResearch articleFirst published 2024

Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System

Mengling Ouyang, Shupeng Zou, Qian Cheng [...]

Therapeutic Advances in Drug Safety

Open accessBrief reportFirst published 2025

Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting System

Afsaneh Shirani, Samuel A. Goldlust, Olaf Stuve

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published October, 2019

Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System

Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published October, 2025

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database

Weixing Zhao, Xiaoni Jin, Yuan Li [...]

Science Progress

Restricted accessResearch articleFirst published June, 2025

Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system

Jiahao Li, Feng Zhang, Ulrich LM Eisel

Journal of Alzheimer’s Disease

Open accessResearch articleFirst published 2024

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System

Huqun Li, Cuilian Guo, Chongshu Wang

Therapeutic Advances in Drug Safety

Open accessResearch articleFirst published January, 2026

Descriptive analysis of anaphylactic events reported in the FDA Adverse Event Reporting System (FAERS)

Nehad Jaser Ahmed

Journal of Public Health Research

Restricted accessResearch articleFirst published November, 2021

Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database

Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray [...]

Respiratory Care

Restricted accessResearch articleFirst published February, 2025

Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data

Wukun Ge, Yingyan Yan, Yaoyao Hu [...]

Journal of Alzheimer’s Disease

Open accessResearch articleFirst published 2025

Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System

Haiyan Mai, Zhenpo Zhang, Yankun Liang [...]

Therapeutic Advances in Drug Safety

Open accessResearch articleFirst published 2024

Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System

Mengling Ouyang, Shupeng Zou, Qian Cheng [...]

Therapeutic Advances in Drug Safety

Open accessBrief reportFirst published 2025

Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting System

Afsaneh Shirani, Samuel A. Goldlust, Olaf Stuve

Therapeutic Advances in Neurological Disorders

Restricted accessResearch articleFirst published October, 2019

Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System

Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published October, 2025

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database

Weixing Zhao, Xiaoni Jin, Yuan Li [...]

Science Progress

Restricted accessResearch articleFirst published June, 2025

Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system

Jiahao Li, Feng Zhang, Ulrich LM Eisel

Journal of Alzheimer’s Disease

Open accessResearch articleFirst published 2024

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System

Huqun Li, Cuilian Guo, Chongshu Wang

Therapeutic Advances in Drug Safety

Open accessResearch articleFirst published January, 2026

Descriptive analysis of anaphylactic events reported in the FDA Adverse Event Reporting System (FAERS)

Nehad Jaser Ahmed

Journal of Public Health Research

Restricted accessResearch articleFirst published November, 2021

Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database

Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray [...]

Respiratory Care

Restricted accessResearch articleFirst published February, 2025

Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data

Wukun Ge, Yingyan Yan, Yaoyao Hu [...]

Journal of Alzheimer’s Disease

Open accessResearch articleFirst published 2025

Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System

Haiyan Mai, Zhenpo Zhang, Yankun Liang [...]

Therapeutic Advances in Drug Safety